SRZN
Surrozen, Inc.
There isn't enough reported data to score SRZN yet.
SRZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
SRZN's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
SRZN PE Valuation
SRZN has no meaningful PE right now: it lost money over the past year.
SRZN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect SRZN's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
SRZN Earnings Per Share
SRZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5M | +409% |
| Q1 2026 | $5M | +409% |
| Q4 2025 | $528K | -19% |
| Q3 2025 | $983K | -90% |
SRZN's revenue is growing: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -207% | +710 points |
| Q1 2026 | -209% | +763 points |
| Q4 2025 | -2394% | -1082 points |
| Q3 2025 | -1107% | -1120 points |
| Q2 2025 | -917% | N/A |
| Q1 2025 | -972% | N/A |
| Q4 2024 | -1312% | N/A |
| Q3 2024 | 12% | N/A |
SRZN's operating margin was −207% last quarter, up 710 points from the same quarter a year ago.
SRZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$4.9M | +$4.2M |
| Q2 2026 | -$7.4M | -$1.3M |
| Q1 2026 | -$12.6M | -$3.3M |
| Q4 2025 | -$5.9M | -270% |
| Q3 2025 | -$9.1M | -$2.3M |
| Q2 2025 | -$6.1M | -$520K |
| Q1 2025 | -$9.3M | -$553K |
| Q4 2024 | $3.5M | +$10.8M |
SRZN has burned cash in almost every quarter: −$31M over the past year, against −$21M the year before.
SRZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +617% | +19.9M shares |
| 1 year | +1054% | +21.1M shares |
SRZN has 23M diluted shares, up 1054% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SRZN Net Leverage
SRZN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SRZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.6 | Neutral |
| Stochastic | 66.5 | Neutral |
SRZN's weekly RSI is 60 (neutral) and its Stochastic is 67 (neutral).
SRZN PE vs Healthcare Sector
SRZN has no meaningful PE right now: it lost money over the past year.
SRZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.7 | 11% above |
| 20 week MA | $24.8 | 28% above |
| 50 week MA | $24.9 | 27% above |
| 100 week MA | $18.1 | 75% above |
| 200 week MA | $14.0 | 127% above |
SRZN is in an uptrend: it's above all five of its weekly moving averages, and 127% above its 200-week average.
SRZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $153.3 | $107.7 | -30% |
| 2022 | $107.7 | $7.95 | -93% |
| 2023 | $7.95 | $9.40 | +18% |
| 2024 | $9.40 | $13.9 | +48% |
| 2025 | $13.9 | $22.2 | +60% |
| 2026 YTD | $22.2 | $31.7 | +43% |
SRZN has finished higher in three of the last five years. It's up 43% so far in 2026.